Evidence map›Paper›PMID 42684559›Full record

ArticleHuman cell2026

Cytokines and chemokines in plasma as markers reflecting immunophenotype of head and neck squamous cell carcinoma.

Susumu Suzuki, Hideaki Ito, Ikuko Okubo, Hitoshi Uga, Niina Iwanaga, Takehiro Hasegawa, Hiromu Nakamura, Daisuke Inukai, Rui Sano, Taishi Takahara and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Susumu Suzuki *Research Creation Support Center, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan. suzukis@aichi-med-u.ac.jp.ORCID http://orcid.org/0000-0002-1466-8824
Hideaki Ito *Department of Pathology, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan.
Ikuko OkuboResearch Creation Support Center, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan.
Hitoshi UgaCentral Research Laboratories, Sysmex Corporation, 4-4-4 Takatsukadai, Nishi-ku, Kobe, 651-2271, Japan.
Niina IwanagaCentral Research Laboratories, Sysmex Corporation, 4-4-4 Takatsukadai, Nishi-ku, Kobe, 651-2271, Japan.
Takehiro HasegawaSysmex R&D Center Europe GmbH, Falkenried 88, 20251, Hamburg, Germany.
Hiromu NakamuraDepartment of Otorhinolaryngology, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan.
Daisuke InukaiDepartment of Otorhinolaryngology, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan.
Rui SanoDepartment of Otorhinolaryngology, Chubu Rosai Hospital, 1-10-6, Koumei, Minato-ku, Nagoya, Aichi, 455-8530, Japan.
Taishi TakaharaDepartment of Surgical Pathology, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan.
Toyonori TsuzukiDepartment of Surgical Pathology, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan.
Tetsuya OgawaDepartment of Otorhinolaryngology, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan.

Funding

Ministry of Education 21K07203Ministry of Education 24K10414
6 · The paper itself

Abstract

Cancer immunophenotypes-immune desert (ID), immune excluded (IE), and immune inflamed (II)-reflect intratumoral immune activity and correlate with immunotherapy efficacy. Serological methods for non-invasive immunophenotyping would be clinically valuable for selecting therapies. We measured plasma concentrations of cytokines (IL-6, IL-10, IL-16, IL-18, VEGF), chemokines (CXCL9, CXCL13), and soluble membrane molecules (sPD-1, sPD-L1, sCTLA-4, sCD163) in 49 patients with head and neck squamous cell carcinoma (HNSCC) and 22 healthy donors using an automated chemiluminescence enzyme immunoassay system. Plasma levels of IL-6, IL-10, VEGF, CXCL9, CXCL13, and sCD163 were significantly higher in patients with HNSCC than in healthy donors. IL-10 levels trended higher in the order ID > IE > II, whereas CXCL9, CXCL13, and sCD163 levels trended higher in the order II > IE > ID. This progressive trend across phenotypes was further enhanced by calculating the ratios of these markers to IL-10. Significantly higher sPD-1 levels were observed in the II phenotype. These results indicate that plasma concentrations and ratios of CXCL9, CXCL13, sCD163, IL-10, and sPD-1 serve as potential surrogate biomarkers reflecting tumor immunophenotypes in HNSCC.

Indexed as

Biomarkers, TumorCarcinoma, Squamous CellChemokinesCytokinesHead and Neck NeoplasmsImmunophenotypingSquamous Cell Carcinoma of Head and NeckAdultAgedAntigens, CDCD163 AntigenFemaleHumansMaleMiddle AgedReceptors, Cell SurfaceAntigens, CDBiomarkers, TumorCD163 AntigenChemokinesCytokinesReceptors, Cell SurfaceBiomarkerCancer immunophenotypeChemokineCytokineHead and neck squamous cell carcinoma

Identifiers

PMID42684559

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.